Platelet Clinical Trials

78 recruitingLast updated: July 25, 2026

There are 78 actively recruiting platelet clinical trials across 31 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1. Top locations include Beijing, Beijing Municipality, China, Houston, Texas, United States, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


Platelet Trials at a Glance

78 actively recruiting trials for platelet are listed on ClinicalTrialsFinder across 6 cities in 31 countries. The largest study group is Not Applicable with 26 trials, with the heaviest enrollment activity in Beijing, Houston, and Boston. Lead sponsors running platelet studies include Beijing Tiantan Hospital, Anhui Provincial Hospital, and Cardiocentro Ticino.

Browse platelet trials by phase

Treatments under study

About Platelet Clinical Trials

Looking for clinical trials for Platelet? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Platelet trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Platelet clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 78 trials

Recruiting
Phase 1

Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency

Inherited Bone Marrow Failure SyndromeFamilial Platelet Disorder With Predisposition to Myeloid Malignancies
National Cancer Institute (NCI)75 enrolled1 locationNCT06090669
Recruiting

Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease

StrokeAcute Ischemic StrokeThrombolysis+2 more
Sigmund Freud PrivatUniversitat462 enrolled8 locationsNCT07299994
Recruiting

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

ThrombophiliaThrombosisSickle Cell Disease+10 more
American Thrombosis and Hemostasis Network3,000 enrolled71 locationsNCT04398628
Recruiting

China Research for Severe Spontaneous Intracerebral Hemorrhage(CRISIH)

Emergency surgeryComplicationsDisorders of Consciousness+2 more
Beijing Tiantan Hospital2,000 enrolled1 locationNCT05975398
Recruiting

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Hodgkin LymphomaNon-Hodgkin LymphomaHematologic Malignancies+14 more
Center for International Blood and Marrow Transplant Research99,999 enrolled142 locationsNCT01351545
Recruiting
Phase 4

Comparison Of Reduced DAPT Followed by P2Y12 Inhibitor Monotherapy With Prasugrel vs stAndard Regimen in STEMI Patients

Dual Antiplatelet TherapyST Elevated Myocardial Infarction
Research Maatschap Cardiologen Rotterdam Zuid1,656 enrolled27 locationsNCT05491200
Recruiting
Phase 3

Canadian Critical Care Comparative Effectiveness Platform

NutritionVasopressorIntensive Care Unit ICU+1 more
Université de Sherbrooke5,500 enrolled9 locationsNCT06605144
Recruiting
Not Applicable

Evaluation of the Efficacy and Safety of Using Platelet-rich Fibrin (PRF)-Based Lipobolus for the Immediate Reconstruction of Defects After Breast-conserving Resection for Breast Cancer (Minimally Invasive Primary Immediate Grafting)

Breast CancerPlatelet-Rich PlasmaLipofilling+1 more
The Leningrad Regional Clinical Hospital30 enrolled1 locationNCT07658170
Recruiting

Efficacy at One Year of Combined Injections of Plasma Rich in Platelets and Hyaluronic Acid in Knee Osteoarthritis

Knee OsteoarthritisHyaluronic AcidPlatelet-Rich Plasma
Centre Hospitalier Universitaire, Amiens100 enrolled1 locationNCT05039463
Recruiting
Phase 1

Protocol Title: Safety and Feasibility of Autologous CD34+ Hematopoietic Stem Cells Mobilization and Apheresis in Participants With RUNX1 Familial Platelet Disorder

RUNX1 Familial Platelet Disorder
M.D. Anderson Cancer Center4 enrolled1 locationNCT06414889
Recruiting
Phase 1

RN1201 Injection in the Treatment of Antibody-Mediated Diseases

Refractory Immune-mediated Platelet Transfusion RefractorinessRelapsed or Refractory Immune Thrombocytopenia
The First Affiliated Hospital of Soochow University9 enrolled1 locationNCT07072247
Recruiting
Phase 4

AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE

Atrial FibrillationStrokePlatelet Aggregation Inhibitors+2 more
University Hospital, Bordeaux60 enrolled2 locationsNCT04796714
Recruiting
Not Applicable

Injectable Platelet-Rich Fibrin With Minimally Invasive Non-Surgical Technique in Treatment of Periodontal Intrabony Defects

Platelet-rich FibrinMinimally Invasive Non-Surgical TechniquePeriodontal Intrabony Defects
October 6 University40 enrolled1 locationNCT07613606
Recruiting
Not Applicable

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

ThrombosisAmputationPlatelet Aggregation Inhibitors+4 more
Massachusetts General Hospital484 enrolled2 locationsNCT07613840
Recruiting
Phase 3

Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.

Coronary Artery DiseasePercutaneous Coronary InterventionAcute Coronary Syndromes+3 more
Cardiocentro Ticino355 enrolled1 locationNCT07582835
Recruiting

Coagulation Factors Alterations in Patients Undergoing Complex Thoraco-abdominal Aortic Aneurysm Repair

Platelet ActivationThoraco-abdominal Aortic Aneurysm RepairCoagulation Factors Alterations
University of Thessaly58 enrolled2 locationsNCT06432387
Recruiting

Minimally Invasive Coronary Artery Bypass Supported by Cangrelor

Coronary Artery DiseaseAntiplatelet TherapyMinimally Invasive Coronary Revascularization Surgery
Cardiocentro Ticino30 enrolled1 locationNCT07514962
Recruiting
Phase 2

Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

Familial Platelet DisorderHematopoietic
M.D. Anderson Cancer Center6 enrolled1 locationNCT06261060
Recruiting

Development of a Device for Evaluating Primary Hemostasis Under Whole Blood Flow Conditions

Von Willebrand DiseasesMajor Constitutional ThrombopathyPatient on Antiplatelet Drugs
Centre Hospitalier Universitaire Dijon200 enrolled2 locationsNCT03773159
Recruiting
Not Applicable

Neonatal Platelet Transfusion Threshold Trial

ThrombosisThrombocytopeniaNeonatal+4 more
NICHD Neonatal Research Network2,433 enrolled20 locationsNCT06676904